Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • BACKGROUND: HPV FOCAL is a randomized trial comparing high-risk HPV [Hybrid Capture 2 (HC2)] vs. liquid-based cytology (LBC) for primary cervical screening. OBJECTIVE: The present study objective was to compare Aptima HPV (AHPV) and HC2 assay performance at the intervention arm baseline and 48 mo. screens in relation to the rates of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+). STUDY DESIGN: Women enrolled after December 2010 (n = 3475) were screened at baseline with both AHPV and HC2 (AHPV was blinded). Women with CIN2+ exited the trial; HC2 negative (-) women and those HC2 positive (+) with


  • Cook, Darrel A
  • Smith, Laurie W
  • Law, Jennifer H
  • Mei, Wendy
  • Gondara, Lovedeep
  • van Niekerk, Dirk J
  • Ceballos, Kathy M
  • Jang, Dan
  • Chernesky, Max
  • Franco, Eduardo L
  • Ogilvie, Gina S
  • Coldman, Andrew J
  • Krajden, Mel

publication date

  • November 2018